

# Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board

2025-04-29

Appointment of renowned gerontologist and mitochondrial biology expert underscores Niagen Bioscience's commitment to advancing cutting-edge NAD+ and healthspan research

LOS ANGELES--(BUSINESS WIRE)-- **Niagen Bioscience, Inc.** (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, is pleased to announce the appointment of Dr. Pinchas Cohen to its **Scientific Advisory Board** (SAB).

**Dr. Cohen** is an **internationally recognized** leading expert in healthy aging and mitochondrial biology. He serves as Dean of the University of Southern California (USC) Leonard Davis School of Gerontology and is a Distinguished Professor of Gerontology, Medicine, and Biological Sciences. He is internationally renowned for pioneering the field of mitochondrial microproteins—newly discovered therapeutic targets for diseases of aging—and has published over 350 scientific papers in top scientific journals focusing on aging, dementia, cancer, diabetes, and the emerging science of microproteins.

Rob Fried, CEO of Niagen Bioscience, remarked, "We are excited to learn from one of the great minds in mitochondrial and longevity research."

His most recent discoveries include the novel microproteins MOTS-c, SHLP, SHMOOSE, and MASL, which represent promising precision-medicine solutions for aging-related diseases in diverse populations. Dr. Cohen is also the founder of the Southern California Aging Research Consortium and two biotech companies, CohBar and MENTSH Therapeutics. His many accolades include the National Institutes of Health (NIH) Director's Transformative Research Award, the Glenn Award for Research in Biological Mechanisms of Aging, and election to both the American Association for the Advancement of Science (AAAS) and the National Academy of Inventors.

Dr. Cohen expressed enthusiasm about the role, noting, "I am honored to join Niagen Bioscience's Scientific Advisory Board. The company's commitment to rigorous scientific research in the field of NAD+ and its impact on aging and metabolic health is truly commendable. I look forward to contributing to their ongoing efforts to enhance healthspan through innovative approaches."

Niagen Bioscience remains dedicated to collaborating with leading scientists to further its mission of improving human health through cutting-edge NAD+ research.

For additional information on Niagen Bioscience, visit [www.niagenbioscience.com](http://www.niagenbioscience.com).

## About Niagen Bioscience:

**Niagen Bioscience, Inc.** (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.

The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.

Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There's a better way to age.

At the heart of its clinically proven product portfolio is Niagen® (patented nicotinamide riboside, or NR), the most efficient, well-researched, high-quality, and legal NAD+ booster available. Niagen powers the Company's consumer supplement, Tru Niagen®, the number one NAD+ boosting oral supplement in the United States† (available at [www.truniagen.com](http://www.truniagen.com)), and Niagen Plus™, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products ([www.niagenplus.com](http://www.niagenplus.com)). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription.

Niagen Bioscience's robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at [www.niagenbioscience.com](http://www.niagenbioscience.com), where copies of press releases, news, and financial information are regularly published.

† Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 1/1/2024 - 12/31/2024).

## Forward Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Niagen Bioscience undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

## Niagen Bioscience Media Contact:

Kendall Knysch, Senior Director of Media Relations & Partnerships

310.405.5227

**[kendall.knysch@niagenbio.com](mailto:kendall.knysch@niagenbio.com)**

## Niagen Bioscience Investor Relations Contact:

Ben Shamsian

Lytham Partners

646-829-9701

**[shamsian@lythampartners.com](mailto:shamsian@lythampartners.com)**

Source: Niagen Bioscience, Inc